Literature DB >> 23502428

Prevalence, associations, and predictors of apathy in adult survivors of infantile (<5 years of age) posterior fossa brain tumors.

Cliodhna Carroll1, Peter Watson, Helen A Spoudeas, Michael M Hawkins, David A Walker, Isabel C H Clare, Anthony J Holland, Howard A Ring.   

Abstract

BACKGROUND: Apathy is associated with pervasive and disadvantageous effects on daily functioning. It has been observed transiently in some children after surgery for posterior fossa tumors. In this study, our objective was to examine prevalence, associations, and predictors of apathy in adult survivors of an infantile posterior fossa brain tumor (PFT).
METHODS: One hundred seventeen adult survivors of a childhood PFT diagnosed before age 5 years and 60 of their siblings were assessed in a cross-sectional study a mean of 32 years (range, 18-53 years) after survivors' initial tumor diagnoses, using the Marin Apathy Evaluation Scale (AES), the Weschler Abbreviated Scale of Intelligence and the Composite International Diagnostic Interview for psychiatric disorders.
RESULTS: Marin Apathy Evaluation Scale, the Weschler Abbreviated Scale of Intelligence reached or exceeded a criterion score for clinically significant apathy in 35% of survivors, compared with 18% in a sibling comparison group. In both siblings and survivors, apathy was associated with lower verbal and full-scale IQ and, among survivors, with having undergone partial rather than total tumor resection (independent of irradiation status). Apathy was not related to presence of concurrent International Classification of Diseases, 10(th) Revision, depression. Female sex was associated with late apathy after a PFT, with increased likelihood of women reaching the apathy criterion relative to men if they were survivors.
CONCLUSIONS: Clinically significant and potentially treatable apathy occurs relatively commonly in adult survivors of an infantile childhood PFT, particularly women. Clinicians, including those managing posterior fossa pathology in very young children, should be aware of this association, and future research should clarify whether specific treatment-related variables are implicated in increasing this risk of apathy.

Entities:  

Mesh:

Year:  2013        PMID: 23502428      PMCID: PMC3607262          DOI: 10.1093/neuonc/nos320

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN: 1522-8517            Impact factor:   12.300


  38 in total

1.  Mood and neurobehavioral correlates of cerebellar lesions.

Authors:  Edward C Lauterbach; Julia B Harris; William F Bina
Journal:  Cogn Behav Neurol       Date:  2010-06       Impact factor: 1.600

2.  Prevalence of neuropsychiatric syndromes in Alzheimer's disease (AD).

Authors:  Jong Chul Youn; Dong Young Lee; Jin Hyeong Jhoo; Ki Woong Kim; Il Han Choo; Jong Inn Woo
Journal:  Arch Gerontol Geriatr       Date:  2010-05-26       Impact factor: 3.250

3.  Reliability and validity of the Apathy Evaluation Scale.

Authors:  R S Marin; R C Biedrzycki; S Firinciogullari
Journal:  Psychiatry Res       Date:  1991-08       Impact factor: 3.222

4.  Neuropsychiatric disorders in persons with severe traumatic brain injury: prevalence, phenomenology, and relationship with demographic, clinical, and functional features.

Authors:  Paola Ciurli; Rita Formisano; Umberto Bivona; Anna Cantagallo; Paola Angelelli
Journal:  J Head Trauma Rehabil       Date:  2011 Mar-Apr       Impact factor: 2.710

Review 5.  Is apathy a valid and meaningful symptom or syndrome in Parkinson's disease? A critical review.

Authors:  Kathleen Rives Bogart
Journal:  Health Psychol       Date:  2011-07       Impact factor: 4.267

6.  The cerebellar cognitive affective syndrome.

Authors:  J D Schmahmann; J C Sherman
Journal:  Brain       Date:  1998-04       Impact factor: 13.501

7.  Tumour type and size are high risk factors for the syndrome of "cerebellar" mutism and subsequent dysarthria.

Authors:  C E Catsman-Berrevoets; H R Van Dongen; P G Mulder; D Paz y Geuze; P F Paquier; M H Lequin
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-12       Impact factor: 10.154

8.  Do people become more apathetic as they grow older? A longitudinal study in healthy individuals.

Authors:  Henry Brodaty; Annette Altendorf; Adrienne Withall; Perminder Sachdev
Journal:  Int Psychogeriatr       Date:  2009-12-15       Impact factor: 3.878

9.  Alcohol consumption patterns and risk factors among childhood cancer survivors compared to siblings and general population peers.

Authors:  E Anne Lown; Robert Goldsby; Ann C Mertens; Thomas Greenfield; Jason Bond; John Whitton; Rachael Korcha; Leslie L Robison; Lonnie K Zeltzer
Journal:  Addiction       Date:  2008-07       Impact factor: 6.526

10.  Long-term outcomes among adult survivors of childhood central nervous system malignancies in the Childhood Cancer Survivor Study.

Authors:  Gregory T Armstrong; Qi Liu; Yutaka Yasui; Sujuan Huang; Kirsten K Ness; Wendy Leisenring; Melissa M Hudson; Sarah S Donaldson; Allison A King; Marilyn Stovall; Kevin R Krull; Leslie L Robison; Roger J Packer
Journal:  J Natl Cancer Inst       Date:  2009-06-17       Impact factor: 11.816

View more
  3 in total

1.  Self- and informant-rated apathy in patients with childhood-onset craniopharyngioma.

Authors:  Aylin Mehren; Jale Özyurt; Paula Zu Klampen; Svenja Boekhoff; Christiane M Thiel; Hermann L Müller
Journal:  J Neurooncol       Date:  2018-07-03       Impact factor: 4.130

2.  Evaluating the diagnostic validity of the cerebellar cognitive affective syndrome (CCAS) in pediatric posterior fossa tumor patients.

Authors:  Doris Hoffmann-Lamplmair; Ulrike Leiss; Andreas Peyrl; Irene Slavc; Thomas Czech; Alexandra Gram; Thomas Pletschko
Journal:  Neurooncol Adv       Date:  2022-05-12

3.  Long-term cognitive outcome in adult survivors of an early childhood posterior fossa brain tumour.

Authors:  Adam P Wagner; Cliodhna Carroll; Simon R White; Peter Watson; Helen A Spoudeas; Michael M Hawkins; David A Walker; Isabel C H Clare; Anthony J Holland; Howard Ring
Journal:  Int J Clin Oncol       Date:  2020-07-08       Impact factor: 3.402

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.